Petros C. Karakousis

Prof. Petros C. Karakousis

Johns Hopkins School of Medicinedisabled, Baltimore, United States
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Microbiology and Molecular Biology Reviews
Verified
Journal Article
Closed access
PDF file
NDNoton Dutta
Noton Dutta
PKPetros C. Karakousis
Petros C. Karakousis
SUMMARY: The aim of this review is to present the current state of knowledge on human latent tuberculosis infection (LTBI) based on clinical studies and observations, as well as experimentalin vitroand animal models. Several key terms are defined, including “latency,” “persistence,” “dormancy,” and “antibiotic tolerance.” Dogmas prevalent in the field are critically examined based on available clinical and experimental data, including the long-held beliefs that infection is either latent or active, that LTBI represents a small population of nonreplicating, “dormant” bacilli, and that caseous granulomas are the haven for LTBI. The role of host factors, such as CD4+and CD8+T cells, T regulatory cells, tumor necrosis factor alpha (TNF-α), and gamma interferon (IFN-γ), in controlling TB infection is discussed. We also highlight microbial regulatory and metabolic pathways implicated in bacillary growth restriction and antibiotic tolerance under various physiologically relevant conditions. Finally, we pose several clinically important questions, which remain unanswered and will serve to stimulate future research on LTBI.

1 March 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
NDNoton Dutta
Noton Dutta
LKLee G. Klinkenberg
Lee G. Klinkenberg
MVMaria-Jesus Vazquez
Maria-Jesus Vazquez
DSDelfina Segura-Carro
Delfina Segura-Carro
GCGonzalo Colmenarejo
Gonzalo Colmenarejo
PKPetros C. Karakousis
Petros C. Karakousis
The stringent response enzyme is a promising new target for Mycobacterium tuberculosis persisters.

7 October 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EAEnoch J. Abbey
Enoch J. Abbey
BKBanda A. A. Khalifa
Banda A. A. Khalifa
MOModupe O. Oduwole
Modupe O. Oduwole
SASamuel K. Ayeh
Samuel K. Ayeh
RNRichard D. Nudotor
Richard D. Nudotor
PKPetros C. Karakousis
Petros C. Karakousis
The ongoing COVID-19 pandemic has devastated many countries with ripple effects felt in various sectors of the global economy. In November 2019, the Global Health Security (GHS) Index was released as the first detailed assessment and benchmarking of 195 countries to prevent, detect, and respond to infectious disease threats. This paper presents the first comparison of Organization for Economic Cooperation and Development OECD countries' performance during the pandemic, with the pre-COVID-19 pandemic preparedness as determined by the GHS Index. Using a rank-based analysis, four indices were compared between select countries, including total cases, total deaths, recovery rate, and total tests performed, all standardized for comparison. Our findings suggest a discrepancy between the GHS index rating and the actual performance of countries during this pandemic, with an overestimation of the preparedness of some countries scoring highly on the GHS index and underestimation of the preparedness of other countries with relatively lower scores on the GHS index.

28 May 2021 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
LZLucas Zhou
Lucas Zhou
SASamuel K. Ayeh
Samuel K. Ayeh
VCVignesh Chidambaram
Vignesh Chidambaram
PKPetros C. Karakousis
Petros C. Karakousis
COVID-19 is a novel disease caused by SARS-CoV-2. During the global vaccination rollout, it is vital to thoroughly understand the modes of transmission of the virus in order to prevent further spread of variants and ultimately to end the pandemic. The current literature suggests that SARS-CoV-2 is transmitted among the human population primarily through respiratory droplets and, to a lesser extent, via aerosols. Transmission appears to be affected by temperature, humidity, precipitation, air currents, pH, and radiation in the ambient environment. Finally, the use of masks or facial coverings, social distancing, and hand washing are effective public health strategies in reducing the risk of exposure and transmission. Additional research is needed to further characterize the relative benefits of specific nonpharmaceutical interventions.

22 May 2014 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
CSCiaran Skerry
Ciaran Skerry
MPMichael L. Pinn
Michael L. Pinn
NBNatalie Bruiners
Natalie Bruiners
RPRichard Pine
Richard Pine
MGMaria L. Gennaro
Maria L. Gennaro
PKPetros C. Karakousis
Petros C. Karakousis
Background The need to develop new, improved treatments for tuberculosis (TB) remains urgent, and the repurposing of existing drugs represents a possible shortcut to market. Recently, there has been significant interest in host-directed adjuvant therapy to enhance bacillary killing. HMG-CoA reductase inhibitors (statins), which are among the most commonly prescribed drugs, have immunomodulatory properties and improve the clinical outcomes of bacterial infections. Methods We studied the tuberculocidal activity of simvastatin alone and in combination with first-line anti-TB drugs in J774 macrophages and during chronic TB infection. Results Exposure to 5 μM simvastatin significantly increased the tuberculocidal activity of isoniazid in J774 macrophages at Day 3 after infection versus isoniazid alone (P = 0.02). Similarly, relative to the standard oral regimen of rifampicin (10 mg/kg), isoniazid (10 mg/kg) and pyrazinamide (150 mg/kg) given five times weekly, the addition of 25 mg/kg simvastatin enhanced bacillary killing, reducing the number of lung cfu by an additional 1 log10 at Day 28 (P < 0.01) and by a further 1.25 log10 at Day 56 (P < 0.01). Conclusions The potential additive activity of simvastatin to first-line TB treatment holds promise. However, further studies to identify the optimal statin and dosing are required. In addition the ability of combination treatment with statins to accelerate the time required to achieve a stable cure remains to be explored.

21 February 2016 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
NDNoton Dutta
Noton Dutta
NBNatalie Bruiners
Natalie Bruiners
MPMichael L. Pinn
Michael L. Pinn
MZMatthew D. Zimmerman
Matthew D. Zimmerman
BPBrendan Prideaux
Brendan Prideaux
PKPetros C. Karakousis
Petros C. Karakousis
The repurposing of existing agents may accelerate TB drug development. Recently, we reported that the lipid-lowering drug simvastatin, when added to the first-line antitubercular regimen, reduces the lung bacillary burden in chronically infected mice. We investigated whether the addition of simvastatin to the first-line regimen (isoniazid/rifampicin/pyrazinamide) shortens the duration of curative TB treatment in mice. Mycobacterium tuberculosis-infected THP-1 cells were exposed to simvastatin to determine the effect of statins on the activity of first-line anti-TB drug activity and intracellular rifampicin concentration. Single-dose and steady-state pharmacokinetic studies guided optimized simvastatin dosing in vivo. BALB/c mice were aerosol-infected with M. tuberculosis H37Rv and drug treatment was initiated 6 weeks post-infection. Separate groups of mice received standard TB treatment with or without simvastatin. Relapse rates were assessed 3 months after discontinuation of each treatment regimen. MALDI-MS imaging was used to image the cholesterol content of mouse lung lesions. Simvastatin significantly enhanced the bactericidal activity of first-line drugs against intracellular M. tuberculosis without altering intracellular rifampicin concentrations. Adjunctive treatment with 60 mg/kg simvastatin shortened the time required to achieve culture-negative lungs from 4.5 to 3.5 months. Following 2.5, 3.5 and 4.5 months of treatment, relapse rates were 100%, 50% and 0%, respectively, in the control group and 50% (P = 0.03), 20% and 0%, respectively, in the statin group. Simvastatin did not alter plasma or lung lesion cholesterol levels. Statins are attractive candidates for host-directed, adjunctive TB therapy. Further preclinical studies are needed to define the optimal statin and dosing.